Literature DB >> 2205784

New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases.

G D Fang1, M Fine, J Orloff, D Arisumi, V L Yu, W Kapoor, J T Grayston, S P Wang, R Kohler, R R Muder.   

Abstract

Three hundred fifty-nine consecutive patients with community-acquired pneumonia admitted to university, community, and VA hospitals underwent a standardized evaluation, including specialized tests for Legionella spp. and Chlamydia pneumoniae (TWAR). The most common underlying illnesses were immunosuppression (36.3%), chronic obstructive pulmonary disease (32.4%), and malignancy (28.4%). The most frequent etiologic agents were Streptococcus pneumoniae (15.3%) and Hemophilus influenzae (10.9%). Surprisingly, Legionella spp. and C. pneumoniae were the third and fourth most frequent etiologies at 6.7% and 6.1%, respectively. Aerobic gram-negative pneumonias were relatively uncommon causes of pneumonia despite the fact that empiric broad-spectrum combination antibiotic therapy is so often directed at this subgroup. In 32.9%, the etiology was undetermined. Antibiotic administration before admission was significantly associated with undetermined etiology (p = 0.0003). There were no distinctive clinical features found to be diagnostic for any etiologic agent, although high fever occurred more frequently in Legionnaires' disease. Clinical manifestations for C. pneumoniae were generally mild, although 38% of patients had mental status changes. Mortality was highest for Staphylococcus aureus (50%) and lowest for C. pneumoniae (4.5%) and Mycoplasma pneumoniae (0%). We document that specialized laboratory testing for C. pneumoniae and Legionella spp. should be more widely used rather than reserved for cases not responding to standard therapy. Furthermore, realization that C. pneumoniae and Legionella spp. are common etiologies for community-acquired pneumonia should affect empiric antibiotic prescription.

Entities:  

Mesh:

Year:  1990        PMID: 2205784     DOI: 10.1097/00005792-199009000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  163 in total

Review 1.  Streptococcus pneumoniae.

Authors:  J R Catterall
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Anaerobic Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

3.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

4.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

5.  Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia.

Authors:  J A Brandenburg; T J Marrie; C M Coley; D E Singer; D S Obrosky; W N Kapoor; M J Fine
Journal:  J Gen Intern Med       Date:  2000-09       Impact factor: 5.128

6.  Antibiotics for pneumonia.

Authors:  M S Bernstein
Journal:  West J Med       Date:  1992-08

7.  Antimicrobial treatment of community acquired pneumonia in adults: A conference report.

Authors:  L Mandell; M Niederman
Journal:  Can J Infect Dis       Date:  1993-01

Review 8.  Quinolones in the treatment of lower respiratory tract infections in adult patients.

Authors:  C Carbon
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Usefulness of PCR and antigen latex agglutination test with samples obtained by transthoracic needle aspiration for diagnosis of pneumococcal pneumonia.

Authors:  A García; B Rosón; J L Pérez; R Verdaguer; J Dorca; J Carratalà; A Casanova; F Manresa; F Gudiol
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Effect of immunosuppressive therapy on the clinical presentation of legionellosis.

Authors:  K Skogberg; P Ruutu; I Koivula; H Jousimies-Somer; V Valtonen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.